French Hospital to Drop Remicade in Favor of a Biosimilar
A large health system will use the biosimilar version of infliximab from Hospira after the company offered a discount of 45%.
Reuters reports that after receiving a 45% discount from Remicade (infliximab), the central purchasing agency for the Assistance Publique-Hôpitaux de Paris (AP-HP) will use the biosimilar version of infliximab instead of branded Remicade.
Remicade accounts for 25% of Johnson & Johnson’s pharmaceutical revenues, according toForbes. Although the patent for Remicade expired in Europe, giving way to biosimilars for that product, the US patent for Remicade does not expire until 2018.
The biosimilar for infliximab was sold to Norway recently for a 69% discount, an even better deal than what France received, though Reuters reports that it was from another supplier. Despite the fact that many analysts initially estimated that biosimilar discounts would be around 15–20%, in reality, the discounts have been significantly larger, a fact that may force branded drug manufacturers to re-evaluate their pricing strategies.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
